A Phase 2 interventional study of Placebo and Pioglitazone in Polycystic Ovary Syndrome (PCOS), sponsored by Fundació Sant Joan de Déu. Recruiting at 7 sites in 6 countries. Open to female participants aged 12 Years to 23 Years. Per ClinicalTrials.gov, last updated 2024-04-22.
Sponsored by Fundació Sant Joan de Déu · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Polycystic Ovary Syndrome with a site in Spain — 3 open to participants now, 3 under way, none of them phase 3. Polycystic Ovary Syndrome · Spain.
Among the 14 studies in Polycystic Ovary Syndrome with a site in Spain, this one has the largest planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is the only one in phase 2, and was the 12th registered.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →3 of the 14 studies in Polycystic Ovary Syndrome with a site in Spain are open now. Recruiting first, the newest first:
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Sites in Spain
Ages 18–45 · Healthy volunteers
Celia Bañuls · Sites in Spain
Ages 18–45 · Women only · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 12 Years to 23 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 4 3
First in 2004; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 364 is above the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 50 across the 10 interventional studies, 60 across the 4 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 14 have an industry lead sponsor. The 10 most frequent:
Fundació Sant Joan de Déu is the lead sponsor of 72 studies on the registry; 21 are open to participants now.
Fundació Sant Joan de Déu has 1 study filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Polycystic Ovary Syndrome with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06551285Celia BañulsStudy of the Effect of a Nutritional Supplement on Microbiota, Metabolic Control, Inflammatory Profile, and Quality of Life in Patients With Polycystic Ovary Syndrome. | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Polycystic Ovary Syndrome with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-centre, multi-national, double-blinded, placebo-controlled, parallel, randomised Phase II clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone and Metformin (SPIOMET) for adolescent girls and young adult women with polycystic ovary syndrome.
Study description: Currently, there is no European Medicines Agency /U.S. Food and Drug Administration (FDA)-approved therapy for polycystic ovary syndrome in adolescent girls and young adult women. Oral contraceptives (OCs) are prescribed off-label to approximately 98% of AYAs with PCOS, including those without pregnancy risk. OCs alleviate key symptoms by inducing a pharmacological combination of anovulatory subfertility, regular pseudo-menses, and extreme elevations of sex hormone-binding globulin (SHBG), but OCs do not revert the underlying pathophysiology, and patients remain at risk for post-treatment subfertility and possibly, for lifelong co-morbidities.
Given the key role of hepato-visceral fat excess in the pathogenesis of PCOS, the prime aim of the treatment should be to achieve a preferential loss of central fat, which should in turn normalise the entire PCOS phenotype. Recent evidence disclosed that a treatment consisting of a fixed low-dose combination of two insulin sensitisers [pioglitazone (PIO) and metformin (MET), with different modes of action], and one mixed anti-androgen and anti-mineralocorticoid (spironolactone), was superior to an OC in normalising the PCOS phenotype, including ovulation rates and hepato-visceral fat.
The study's main goals are to assess the efficacy, tolerability and safety of a new treatment (SPIOMET) for adolescent girls and young adult women with polycistic ovarian syndrome; the comparison (in this order) of each SPIOMET, spironolactone and pioglitazone (SPIO) and PIO over placebo; and in addition, the comparison of SPIOMET over PIO and over SPIO (in this order).
Primary Objective: To test the efficacy of SPIOMET in normalising ovulation rate in adolescents and young adult women with PCOS.
Secondary Objectives: To test the efficacy of SPIOMET in normalising the endocrine-metabolic status, to describe the drug safety profile and to assess the adherence and subjective acceptability, as well as the quality of life of the participating subjects.
This is a multi-centre, multi-national, double-blinded, placebo-controlled, parallel, randomised Phase II clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone and Metformin (SPIOMET) for adolescent girls and young adult women (AYAs) with polycystic ovary syndrome (PCOS).
Study description: Currently, there is no European Medicines Agency (EMA)/U.S. Food and Drug Administration (FDA)-approved therapy for PCOS in AYAs. Oral contraceptives (OCs) are prescribed off-label to approximately 98% of AYAs with PCOS, including those without pregnancy risk. OCs alleviate key symptoms by inducing a pharmacological combination of anovulatory subfertility, regular pseudo-menses, and extreme elevations of sex hormone-binding globulin (SHBG), but OCs do not revert the underlying pathophysiology, and patients remain at risk for post-treatment subfertility and possibly, for lifelong co-morbidities.
Given the key role of hepato-visceral fat excess in the pathogenesis of PCOS, the prime aim of the treatment should be to achieve a preferential loss of central fat, which should in turn normalise the entire PCOS phenotype. Recent evidence disclosed that a treatment consisting of a fixed low-dose combination of two insulin sensitisers [pioglitazone (PIO) and metformin (MET), with different modes of action], and one mixed anti-androgen and anti-mineralocorticoid (spironolactone), was superior to an OC in normalising the PCOS phenotype, including ovulation rates and hepato-visceral fat.
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: Placebo
Pioglitazone
Drug: Pioglitazone
Spironolactone and Pioglitazone
Drug: Pioglitazone · Drug: Spironolactone
Spironolactone, Pioglitazone and Metformin
Drug: Pioglitazone · Drug: Spironolactone · Drug: Metformin
Comparator arm with placebo
Pioglitazone 7.5 mg/day
Also known as: PIO
Spironolactone 50 mg/day
Also known as: S
Metformin 850 mg/day
Also known as: MET
On-treatment ovulation rate.
On-treatment ovulation rate.
Time frame: Following end of each two 12-week on-treatment periods (month 0-3 and month 9-12)
Post-treatment ovulation rate.
Post-treatment ovulation rate.
Time frame: Following the end of post-treatment period (month 12-15)
Clinical variable: hirsutism
Presence of hirsutism as measured by the modified Ferriman \& Gallwey score
Time frame: Every 3 months from study start to study completion (estimated 18 months)
Clinical variable: Acne
Presence of Acne as evaluated using the Leeds Acne Grading Scale
Time frame: Every 3 months from study start to study completion (estimated 18 months)
Clinical variable: menstrual regularity
Assessment of the menstrual regularity
Time frame: Every 3 months from study start to study completion (estimated 18 months)
Circulating androgens
Assessment by measurement of circulating androgens
Time frame: Every 3 months from study start to study completion (estimated 18 months)
Lipids
Assessment by measurement of total cholesterol, low-density lipoprotein (LDL-cholesterol), high-density lipoprotein (HDL- cholesterol), triglycerides;
Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Insulinaemia
Fasting and 2 hours after a 75-gr oral glucose load \[oral glucose tolerance test (oGTT). Estimation of insulin resistance from fasting insulin and glucose levels using the homeostasis model assessment (HOMA);
Time frame: Baseline and at the end of treatment (month 12) and 6 months after treatment
Inflammation markers
Inflammation markers
Time frame: Baseline and at the end of treatment (month 12) and 6 months after treatment
Insulin sensitivity
Insulin sensitivity
Time frame: Baseline and at the end of treatment (month 12) and 6 months after treatment
Ultra-sensitive C-reactive protein (us-CRP);
Ultra-sensitive C-reactive protein (us-CRP);
Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Growth-and- differentiation factor-15 (GDF15);
Growth-and- differentiation factor-15 (GDF15);
Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
High molecular weight adiponectin (HMW-adip),
High molecular weight adiponectin (HMW-adip),
Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
C-X-C motif chemokine ligand 14 (CXCL14) (69,81);
C-X-C motif chemokine ligand 14 (CXCL14) (69,81);
Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Epigenetic variable
Circulating microRNA 451-a (miR-451a) concentrations (88);
Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Imaging: Cardiovascular risk
As measured by ultrasound
Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Imaging: Body composition
As measured by dual-energy X-ray absorptiometry (DXA)
Time frame: Baseline and at the end of treatment (month 12) and 6 months after treatment
Imaging: Abdominal fat distribution (subcutaneous and visceral)
As measured by MRI
Time frame: Baseline and at the end of treatment (month 12) and 6 months after treatment
Imaging:hepatic fat
As measured by MRI
Time frame: Baseline and at the end of treatment (month 12) and 6 months after treatment
Abdominal fat distribution
Waist circumference, Waist to hip ratio (WHR), and hepatic fat by MRI
Time frame: Baseline and at the end of treatment (month 12) and 6 months after treatment
Weight
Weight measurement
Time frame: Every 3 months from study start to study completion (estimated 18 months)
Improvement of co-morbidities
Improvement of co-morbidities
Time frame: Every 3 months from study start to study completion (estimated 18 months)
Improvement of health behaviour
Improvement of health behaviour
Time frame: Every 3 months from study start to study completion (estimated 18 months)
Improvement of health-related quality of life (HRQoL)
As reported by the patient
Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Safety laboratory tests
Blood count, electrolyte panel, urea, alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyltransferase (GGT), creatinine, vitamin B12 and folic acid;
Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Adverse events (AEs)
As reported by the patient
Time frame: Every 3 months from study start to study completion (estimated 18 months)
Adherence
Adherence will be calculated as the ratio between the number of tablets prescribed and dispensed for the period between hospital appointments and the number of tablets returned by the patient at the following appointment;
Time frame: Every 3 months from study start to study completion (estimated 18 months)
Acceptability of the treatment
Acceptability of the tablet by the study patients
Time frame: Every 3 months from study start to study completion (estimated 18 months)
PROMs (patient-reported outcomes)
Questionnaire SF-36
Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
PROMs (patient-reported outcomes)
Questionnaire PCOSQ
Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
HRQoL (health-related quality of life)
Questionnaire SF-36
Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
HRQoL (health-related quality of life)
Questionnaire PCOSQ
Time frame: Baseline, at month 3, month 6 and month 12 whiled on treatment and 6 months after the end of treatment
Plan to share: No
No publications or documents are linked to this record.
Started May 2022 (actual). Primary completion is estimated for Apr 2025, 35 months after the start.
Of 23 phase 2 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 29. This study's planned 35 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pioglitazone · Spironolactone · Metformin
Fundació Sant Joan de Déu